Pathological overproduction: the bad side of adenosine

被引：103

作者：

Borea, Pier Andrea ^{[1
]}

Gessi, Stefania ^{[1
]}

Merighi, Stefania ^{[1
]}

Vincenzi, Fabrizio ^{[1
]}

Varani, Katia ^{[1
]}

机构：

[1] Univ Ferrara, Dept Med Sci, I-44121 Ferrara, Italy

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 2017年 / 174卷 / 13期

关键词：

PROTEIN-COUPLED RECEPTOR; CEREBRAL ISCHEMIC-INJURY; CENTRAL-NERVOUS-SYSTEM; HUMAN BREAST-CANCER; A(2A) RECEPTORS; A2A RECEPTOR; THERAPEUTIC TARGETS; PARKINSONS-DISEASE; A(2B) RECEPTORS; CAFFEINE INTAKE;

D O I：

10.1111/bph.13763

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Adenosine is an endogenous ubiquitous purine nucleoside, which is increased by hypoxia, ischaemia and tissue damage and mediates a number of physiopathological effects by interacting with four GPCRs, identified as A(1), A(2A), A(2B) and A(3). Physiological and acutely increased adenosine is mostly associated with beneficial effects that include vasodilatation and a decrease in inflammation. In contrast, chronic overproduction of adenosine occurs in important pathological states, where long-lasting increases in the nucleoside levels are responsible for the bad side of adenosine associated with chronic inflammation, fibrosis and organ damage. In this review, we describe and critically discuss the pathological overproduction of adenosine and analyse when, where and how adenosine exerts its detrimental effects throughout the body.

引用

页码：1945 / 1960

页数：16

共 201 条

[1]

Epithelial-specific A2B adenosine receptor signaling protects the colonic epithelial barrier during acute colitis [J].

Aherne, C. M. ;

Saeedi, B. ;

Collins, C. B. ;

Masterson, J. C. ;

McNamee, E. N. ;

Perrenoud, L. ;

Rapp, C. R. ;

Curtis, V. F. ;

Bayless, A. ;

Fletcher, A. ;

Glover, L. E. ;

Evans, C. M. ;

Jedlicka, P. ;

Furuta, G. T. ;

de Zoeten, E. F. ;

Colgan, S. P. ;

Eltzschig, H. K. .

MUCOSAL IMMUNOLOGY, 2015, 8 (06) :1324-1338

[2]

THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors [J].

Alexander, Stephen P. H. ;

Davenport, Anthony P. ;

Kelly, Eamonn ;

Marrion, Neil ;

Peters, John A. ;

Benson, Helen E. ;

Faccenda, Elena ;

Pawson, Adam J. ;

Sharman, Joanna L. ;

Southan, Christopher ;

Davies, Jamie A. ;

Aldrich, R. ;

Attali, B. ;

Back, M. ;

Barnes, N. M. ;

Bathgate, R. ;

Beart, P. M. ;

Becirovic, E. ;

Biel, M. ;

Birdsall, N. J. ;

Boison, D. ;

Brauner-Osborne, H. ;

Broeer, S. ;

Bryant, C. ;

Burnstock, G. ;

Burris, T. ;

Cain, D. ;

Calo, G. ;

Chan, S. L. ;

Chandy, K. G. ;

Chiang, N. ;

Christakos, S. ;

Christopoulos, A. ;

Chun, J. J. ;

Chung, J. -J. ;

Clapham, D. E. ;

Connor, M. A. ;

Coons, L. ;

Cox, H. M. ;

Dautzenberg, F. M. ;

Dent, G. ;

Douglas, S. D. ;

Dubocovich, M. L. ;

Edwards, D. P. ;

Farndale, R. ;

Fong, T. M. ;

Forrest, D. ;

Fowler, C. J. ;

Fuller, P. ;

Gainetdinov, R. R. .

BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (24) :5744-5869

[3]

THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Enzymes [J].

Alexander, Stephen P. H. ;

Fabbro, Doriano ;

Kelly, Eamonn ;

Marrion, Neil ;

Peters, John A. ;

Benson, Helen E. ;

Faccenda, Elena ;

Pawson, Adam J. ;

Sharman, Joanna L. ;

Southan, Christopher ;

Davies, Jamie A. ;

Aldrich, R. ;

Attali, B. ;

Back, M. ;

Barnes, N. M. ;

Bathgate, R. ;

Beart, P. M. ;

Becirovic, E. ;

Biel, M. ;

Birdsall, N. J. ;

Boison, D. ;

Brauner-Osborne, H. ;

Broeer, S. ;

Bryant, C. ;

Burnstock, G. ;

Burris, T. ;

Cain, D. ;

Calo, G. ;

Chan, S. L. ;

Chandy, K. G. ;

Chiang, N. ;

Christakos, S. ;

Christopoulos, A. ;

Chun, J. J. ;

Chung, J. -J. ;

Clapham, D. E. ;

Connor, M. A. ;

Coons, L. ;

Cox, H. M. ;

Dautzenberg, F. M. ;

Dent, G. ;

Douglas, S. D. ;

Dubocovich, M. L. ;

Edwards, D. P. ;

Farndale, R. ;

Fong, T. M. ;

Forrest, D. ;

Fowler, C. J. ;

Fuller, P. ;

Gainetdinov, R. R. .

BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (24) :6024-6109

[4]

THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Transporters [J].

Alexander, Stephen P. H. ;

Kelly, Eamonn ;

Marrion, Neil ;

Peters, John A. ;

Benson, Helen E. ;

Faccenda, Elena ;

Pawson, Adam J. ;

Sharman, Joanna L. ;

Southan, Christopher ;

Davies, Jamie A. ;

Aldrich, R. ;

Attali, B. ;

Back, M. ;

Barnes, N. M. ;

Bathgate, R. ;

Beart, P. M. ;

Becirovic, E. ;

Biel, M. ;

Birdsall, N. J. ;

Boison, D. ;

Brauner-Osborne, H. ;

Broeer, S. ;

Bryant, C. ;

Burnstock, G. ;

Burris, T. ;

Cain, D. ;

Calo, G. ;

Chan, S. L. ;

Chandy, K. G. ;

Chiang, N. ;

Christakos, S. ;

Christopoulos, A. ;

Chun, J. J. ;

Chung, J. -J. ;

Clapham, D. E. ;

Connor, M. A. ;

Coons, L. ;

Cox, H. M. ;

Dautzenberg, F. M. ;

Dent, G. ;

Douglas, S. D. ;

Dubocovich, M. L. ;

Edwards, D. P. ;

Farndale, R. ;

Fong, T. M. ;

Forrest, D. ;

Fowler, C. J. ;

Fuller, P. ;

Gainetdinov, R. R. ;

Gershengorn, M. A. .

BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (24) :6110-6202

[5]

Immunosuppressive activities of adenosine in cancer [J].

Allard, Bertrand ;

Beavis, Paul A. ;

Darcy, Phillip K. ;

Stagg, John .

CURRENT OPINION IN PHARMACOLOGY, 2016, 29 :7-16

[6]

[Anonymous], ADENOSINE A2A RECEPT

[7]

[Anonymous], NEUROL SCI

[8]

Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities [J].

Antonioli, Luca ;

Yegutkin, Gennady G. ;

Pacher, Pal ;

Blandizzi, Corrado ;

Hasko, Gyorgy .

TRENDS IN CANCER, 2016, 2 (02) :95-109

[9]

Adenosine signalling in diabetes mellitus-pathophysiology and therapeutic considerations [J].

Antonioli, Luca ;

Blandizzi, Corrado ;

Csoke, Balazs ;

Pacher, Pal ;

Hasko, Gyoergy .

NATURE REVIEWS ENDOCRINOLOGY, 2015, 11 (04) :228-241

[10]

Adenosine pathway and cancer: where do we go from here? [J].

Antonioli, Luca ;

Hasko, Gyoergy ;

Fornai, Matteo ;

Colucci, Rocchina ;

Blandizzi, Corrado .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (09) :973-977

← 1 2 3 4 5 6 7 8 9 10 →